Prophylactic Pylorus Dilatation prior to Esophagectomy Randomized trial
Not Applicable
- Conditions
- C15Malignant neoplasm of oesophagus
- Registration Number
- DRKS00034360
- Lead Sponsor
- niversitätsmedizin Mainz, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 118
Inclusion Criteria
Histological proven squamous cell carcinoma or adenocarcinoma of the intrathoracic esophagus or gastroesophageal junction, planned as minimally invasive esophagectomy (RAMIE/MIE) with intrathoracic anastomosis.
Surgical resectability, cT1-4a, cNx, cM0
Age = 18 and = 80
ECOG performance status 0 – 2
Written consent
Exclusion Criteria
Carcinoma of the cervical esophagus
Functional inoperability
Preoperation concerning the stomach or the pylorus
Esophageal stenosis at time of potential study inclusion
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rate of pyloric dysfunction
- Secondary Outcome Measures
Name Time Method Major and minor postoperative complication rates, adverse events during gastroscopy, mortality, length of ICU and hospital stay and quality of life
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link pylorus dilatation to reduced postoperative complications in esophagectomy for C15 esophageal cancer?
How does prophylactic pylorus dilatation compare to standard preoperative care in preventing gastric stasis after esophagectomy for malignant esophageal tumors?
Which biomarkers correlate with successful pylorus dilatation outcomes in patients undergoing esophagectomy for esophageal adenocarcinoma?
What are the potential adverse events of pylorus dilatation in esophagectomy and their clinical management strategies?
Are there combination approaches involving pylorus dilatation and pharmacological agents to optimize postoperative recovery in esophageal cancer surgery?